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Background: Psoriasis is a complex disease associated with multiple comorbidities, including metabolic syndrome and leaky
gut syndrome. Dietary lifestyle interventions have been reported to affect the disease in terms of lesional severity. It remains
unclear how diets affect these comorbidities and the general health in psoriasis patients. Modified Intermittent Fasting (MIF) on
2 non-consecutive days has shown beneficial effects on metabolic parameters. A significant advantage of MIF over the currently
investigated dietary changes is its feasibility.
Objective: Here, we aim to study the effects of MIF on skin, gut and metabolic health in psoriasis patients.
Methods: A two-arm pilot prospective cross-over randomized control trial (RCT) will be performed in 20 patients with psoriasis
as a pilot study. Patients will be randomized 1:1 to either start with MIF and subsequent regular diet for 12 weeks each or to start
with regular diet and subsequent MIF for 12 weeks each. The following parameters will be assessed: demographics, disease
phenotype, medical and familial history, psoriasis severity, dermatology-specific and general quality of life, nutritional and
physical habits, mental and intestinal health, intestinal and cutaneous integrity, inflammatory and metabolic markers, and
satisfaction.
Results: The aim is to uncover the effects of MIF on psoriasis severity and gut health integrity through clinical and molecular
investigation. More precisely, we want to map the evolution of the different markers in response to MIF as compared to the
regular diet, such as psoriasis severity, permeability and inflammation.
Conclusions: Understanding how dietary lifestyles can affect epithelial lineages such as the skin and gut, will greatly improve
our understanding on the development of psoriasis and may pose a non-pharmacological venue for treatments. Clinical Trial:
ClinicalTrials.gov, NCT04418791. Registered June 5 2020, https://clinicaltrials.gov/ct2/show/NCT04418791. Current protocol
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Abstract:
BACKGROUND:  Psoriasis  is  a  complex  disease  associated  with  multiple
comorbidities, including metabolic syndrome and leaky gut syndrome. Dietary
lifestyle  interventions  have  been  reported  to  affect  the  disease  in  terms  of
lesional severity. It remains unclear how diets affect these comorbidities and the
general  health  in  psoriasis  patients.  Modified Intermittent  Fasting (MIF)  on  2
non-consecutive days has shown beneficial effects on metabolic parameters. A
significant advantage of MIF over the currently investigated dietary changes is
its feasibility.  
OBJECTIVES: Here, we aim to study the effects of MIF on skin, gut and metabolic
health in psoriasis patients.
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METHODS: A two-arm pilot prospective cross-over randomized control trial (RCT)
will be performed in 20 patients with psoriasis as a pilot study. Patients will be
randomized 1:1  to  either  start  with  MIF  and  subsequent  regular  diet  for  12
weeks each or to start with regular diet and subsequent MIF for 12 weeks each.
The following parameters will be assessed: demographics, disease phenotype,
medical  and  familial  history,  psoriasis  severity,  dermatology-specific  and
general  quality  of  life,  nutritional  and  physical  habits,  mental  and  intestinal
health, intestinal and cutaneous integrity, inflammatory and metabolic markers,
and satisfaction. 
RESULTS: A total of 24 participants have been enrolled in the study. The final
visit is foreseen for June 2021.
CONCLUSIONS: The aim is to uncover the effects of MIF on psoriasis severity and
gut health integrity through clinical and molecular investigation. More precisely,
we want to map the evolution of the different markers in response to MIF as
compared  to  the  regular  diet,  such  as  psoriasis  severity,  permeability  and
inflammation. Understanding how dietary lifestyles can affect epithelial lineages
such  as  the  skin  and  gut,  will  greatly  improve  our  understanding  on  the
development  of  psoriasis  and  may  pose  a  non-pharmacological  venue  for
treatments. 
TRIAL REGISTRATION: ClinicalTrials.gov, NCT04418791. Registered June 5 2020,
https://clinicaltrials.gov/ct2/show/NCT04418791.  Current  protocol  date/version:
May 20 2020
Keywords: Modified Intermittent Fasting, psoriasis, leaky gut, permeability, gut-
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skin  axis,  dietary  intervention,  epithelial  integrity,  chronic  skin  disease,
intermittent fasting
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INTRODUCTION
Psoriasis is a prevalent and chronic skin disease characterized by red, scaly and
thickened skin lesions. The extent of the lesions determines the severity of the
disease, commonly defined by the Psoriasis Area and Severity Index (PASI). The
disease has a significant impact on quality of life (QoL) [1]. Currently, no cure is
available, and the disease is mainly treated symptomatically. 
Psoriasis is a complex and multifactorial disease that remains to be understood
more thoroughly. Though genetic factors such as polymorphisms in  PSORS1-9,
IL12B, IL23R and  IL28RA  play a role [2], disease development and severity is
also heavily affected by factors such as obesity, stress and smoking  [3]–[11].
Our recent understanding of its pathophysiology has led to the development of
drugs  targeting  disease-mediating  cytokines  such  as  Tumour  Necrosis  Factor
alpha  (TNF-α),  Interleukin  (IL)-17,  and  the  subunits  of  IL-23  p40  and  p19.
Interestingly,  the  same  cytokines  also  play  important  roles  in  comorbidities
associated with psoriasis  [12], [13]. Indeed, the disease complexity is evident
from the associated physical and mental comorbidities, including cardiovascular
diseases, metabolic syndrome, depression and leaky gut syndrome  [14], [15],
[24], [25], [16]–[23]. The latter is especially interesting, since it is characterized
by an impaired intestinal barrier, and hence shows parallels with psoriatic skin
which is also characterized by an impaired cutaneous barrier. The link between
the gut and skin has been postulated several times and has been termed gut-
skin  axis  [26],  [27].  In  the psoriasiform ‘imiquimod’  murine  model,  we have
shown  that  gut-mediated  inflammation  drove  the  extent  of  the  cutaneous
lesions,  mediated  by  the  production  of  type  I  interferon  beta  (IFN-β)  [28],
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underscoring  that  gut  health  can  affect  skin  health.  In  humans,  intestinal
permeability  in  psoriasis  has  been  reported  previously  [24],  [29],  [30],
underscoring the existence of an aberrant gut-skin axis in the disease as well. 
The effect of dietary interventions has not been investigated in psoriasis related
to this gut-skin axis, as the focus has mainly been on the skin only. Indeed,
different  studies  have  been  conducted  to  investigate  the  effects  of  diets  in
psoriasis. For instance, a gluten-free diet was associated with a positive effect
on psoriasis severity in patients who tested positive for gluten sensitivity [31],
[32]. Another study investigating a diet aimed at weight loss showed a favorable
outcome on psoriasis and the QoL, especially in patients with obesity [33]. This
confirmed  the  findings  of  an  earlier  study  that  combined  diet  with  physical
exercise for weight loss [34]. Interestingly, treatment response can be improved
by  a  very  low-calorie  ketogenic  diet  [35].  We  also  reported  that  treatment
response  to  secukinumab,  an  IL-17  blocker  for  psoriasis  treatment,  may  be
negatively impacted by weight [36]. Recently, long-term weight loss was found
favorable for  psoriasis  [37].  In  2019,  a fasting diet  related to Ramadan was
conducted where participants had their meals and drinks, including water, only
during evening hours  [38]. This diet was found to be favorable for psoriasis,
especially in patients treated with apremilast or mTOR inhibitors. More recently,
an aggressive ketogenic weight-loss program led to a significant reduction in
disease severity in drug-naive psoriasis patients who were overweight or obese
[39].  Despite  the  positive  effects  of  dietary  changes  on  psoriasis  outcomes,
feasibility  for  daily  implementation  and  effectiveness  heavily  depend  on
adherence.  Gibson  and  Sainsbury  propose  strategies  to  increase  adherence,
https://preprints.jmir.org/preprint/26405 [unpublished, peer-reviewed preprint]
JMIR Preprints Grine et al
including avoiding overcompensation of caloric restrictions and tailoring to the
individual’s  needs  [40].  Here,  we aim to  investigate  the  effects  of  modified
intermittent fasting (MIF), more specifically the 5:2 diet. In this diet, participants
restrict their caloric uptake to 500 kilocalories (kcal) on 2 non-consecutive days
per week. MIF has been associated with positive outcomes on plasma insulin
levels, fat-to-lean ratio and other cardiovascular disease risk factors  [41]–[44],
yet its effects on psoriasis and gut health remains to be investigated. It has a
successful  adherence  rate  as  it  reduces  the  drive  to  overcompensate  the
calorie-restriction and allows the individual to incorporate the calorie-restricting
days  to  their  own scheme (tailored),  reflecting  the  conditions  postulated  by
Gibson and Sainsbury for optimal adherence [40].
Here, we present the study protocol of the study entitled “Modified Intermittent
Fasting in Psoriasis (MANGO)”: a randomized controlled open cross-over clinical
trial to investigate the effects of a dietary intervention on the gut-skin axis in
patients with psoriasis. The MANGO study will provide mechanistic evidence to
inform whether there is a link between gut health and psoriatic lesions and give
us insight  in  the benefit  of  MIF  in  psoriasis  management and a  consequent
landmark shift in the holistic view of a chronic skin disease.
METHODS
We aim to investigate the impact of  a MIF diet in patients affected by mild
psoriasis on skin and gut health based on various markers. The main hypothesis
is that a 5:2 diet over the course of 12 weeks will improve skin lesions and gut
health  biomarkers,  in  comparison  to  a  standard  diet.  This  study  has  been
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registered on clinicaltrials.gov (NCT04418791) and has been approved by the
ethics committee of the Ghent University Hospital (B6702020000141). The trial
will be conducted according to the Declaration of Helsinki.
Primary objective
Comparison of MIF with a standard diet in terms of the proportion of patients
obtaining an improvement in absolute PASI score from baseline, during or at the
end of the 12 weeks post-intervention to prove superiority of MIF.
Secondary objectives
Comparison of MIF with a standard diet, during or at the end of the 12 weeks
post-intervention in the following aspects:
 Differences  in  total  body  fat,  weight,  BMI,  and/or  waist  circumference
during and after intervention to baseline
 Differences in inflammation markers in serum and/or skin during and after
intervention to baseline
 Differences in metabolic markers in serum and/or skin during and after
intervention to baseline
 Differences in permeability markers in serum, skin, gut and/or feces during
and after intervention to baseline
 Correlation to dietary intake and/or disease severity
 Score of subject’s rating of satisfaction on intervention
Finally, the number of subjects who completed the study or single intervention
window  successfully  will  also  be  assessed  to  give  us  insights  about  the
feasibility of the diet. 
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Study design
Open randomized controlled cross-over clinical trial to test the effects of MIF on the gut-
skin axis in 20 adults with psoriasis. The total study duration is 34 weeks: 2 moments
are  included  as  baseline  prior  to  randomization  (week  0  and  2).  Randomization  is
performed the Research Electronic Data Capture (REDCap) software’s randomization
module  upon  inclusion.  Post-randomization,  patients  are  assigned  to  either  the
intervention or control arm. This study is a cross-over design, and patients will switch
arms  at  week  14  (Figure  1).  Evaluations  include  clinical,  biochemical  and  patient
reported outcomes. Intermediate time points are included at weeks 8 and 20. Each
subject will be in the study for a total of 26 weeks, with a single follow-up at week 34
after  completing  the  second  arm.  The  entire  trial  will  run  for  12  months,  with  a
recruitment period of 3 months.
Recruitment, eligibility and randomization
Subjects are patients who attend the PsoPlus clinic at the Department of Dermatology
at the Ghent University Hospital or who are willing to attend the PsoPlus clinic for the
study visits. An additional call will be launched through the Flemish Psoriasis League for
people with psoriasis to be screened and enrolled. A recruitment target of maximal 30
adult subjects will be recruited through consecutive sampling. Subjects should have a
clinical diagnosis of mild psoriasis vulgaris. Mild psoriasis is defined as a score of 10 or
less based on PASI. Eligibility criteria are listed further in Table 1. Subjects who meet
any of the exclusion criteria at the time of enrollment or during the study period, will be
excluded from study participation. Subjects will  be allocated in a 1:1 manner to the
control  or  intervention  arm,  using  stratified  randomization with  variable  permuted
blocks with concealment of allocation based on age, gender and BMI, with a maximum
of 15 subjects per arm.  
Study interventions
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Upon inclusion, subjects are expected to record their dietary and exercise habits for 2
full weeks using the MyFitnessPal app. Baseline measurements consists of two different
time points: inclusion (week 0) and randomization (week 2), which will be averaged for
analysis.  Upon  randomization,  subjects  are  assigned  to  either  the  control  or
intervention arm in a 1:1 ratio. The intervention consists of a dietary intervention based
on the 5:2 fasting diet. Subjects will perform MIF, where they will be asked to consume
a total of 500 kcal in a window of 6 hours or less from 8:00 am till 2:00 pm, twice per
week on 2 non-consecutive days. Subjects will receive a leaflet with examples of what
500 kcal constitutes. This intervention will last for 12 weeks, from randomization. The
control arm resembles the baseline period where subjects can eat without restriction,
for 12 weeks. A digital food diary will be completed using the MyFitnessPal app and
subjects are asked to use the TARGID tag [45] present in the app’s database. Subjects
are expected to record their  dietary and exercise habits  twice a week through the
MyFitnessPal app (on the fasting days in the intervention arm). The Food Frequency
Questionnaire (FFQ) will be recorded during all visits to assess for any dietary changes.
Clinical  evaluation  will  be  performed  during  PsoPlus  consultations  held  at  the
Department  of  Dermatology  at  the  Ghent  University  Hospital  by  the  treating
dermatologist  and  specialized  nurse.  Questionnaires  regarding  quality  of  life  are
completed  in  the  waiting  room  prior  to  the  consultation;  questionnaires  regarding
dietary and exercise habits are completed at home by the patient. Demographic and
clinical data will be collected, in addition to serum, skin (via tape stripping), feces, and
data through the app MyFitnessPal, and questionnaires for patient-reported outcomes
(Table 2). 
Outcome measures
Table  2  lists  the  parameters  per  study  visit.  During  the  study,  data  on
demographics will be collected including age, gender, and medical and familial
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history.  Furthermore,  the  disease  phenotype  will  be  assessed  and  psoriasis
severity will be evaluated by an independent assessor. In addition to psoriasis-
related parameters, the clinical assessment will include metabolic parameters
such as weight, waist circumference, BMI, and total body fat. Lifestyle habits will
be registered: patients will keep a diary  twice a week their diet in the online
app MyFitnessPal (MFP); in the intervention arm this will be done on the fasting
days. General diet and physical exercise habits will  be recorded via the Food
Frequency  Questionnaire  (FFQ)  and  the  International  Physical  Activity
Questionnaire (IPAQ), respectively. Questionnaires will also be used to evaluate
quality  of  life  and  mental  health,  including  Dermatology  Life  Quality  Index
(DLQI),  EuroQol-5  Dimension-5  Level  (EQ-5D-5L),  Hospital  Anxiety  and
Depression Scale (HADS), Beck’s Depression Index (BDI), Perceived Stress Scale
(PSS), and a Visual Analogue Scale (VAS) for satisfaction. 
Cutaneous  barrier  integrity  will  be  checked  through  the  measurement  of
transepidermal water loss (TEWL) at 2 different body sites: one perilesional and
one non-lesional site. These will be documented to ensure measurement at the
same body sites throughout the study. 
Intestinal barrier integrity will be assessed in 2 serological and fecal samples.
Permeability markers zonulin, claudin-3, Ileal Fatty Acid Binding Protein (I-FABP)
will be quantified in serum, and calprotectin (S100A8/S100A9) will be measured
in both serum and stool samples. Participants will also be asked to report on
intestinal  symptoms  based  on  the  Dutch  questionnaire  for  Irritable  Bowel
Syndrome (Prikkelbaar Darm Syndroom Questionnaire; PDSQ). 
Serological levels of inflammatory and metabolic messengers such as IL-6, TNF-
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alpha, leptin and adiponectin will be measured in serum and skin. The latter will
be collected through skin tape stripping at the same body sites where TEWL
measurement is performed. 
Finally,  microbiome sampling will  be performed through cutaneous and fecal
samples for future follow-up projects.
Study  visits  will  be  planned  on  the  fasting  days  and  participants  will  be
scheduled as such to account for circadian rhythm and reduce intra-individual
variability.
Sample size calculations
The  sample  size  was  determined  by  power  analyses  and  available  study  budget.
Sample size was calculated with the power calculator of masc.org.au, applying a two-
tailed t test with  alpha  at  0.05  and  power  at  0.80.  The  predicted  effect  size  was
estimated based on a prior study of intermittent fasting [38]. We estimated that at a
two-sided  p-value  of  0.05  and with  80% power,  we  would  need 16 participants  to
complete the study to detect a within-individual effect size of 0.75 standard deviations.
We  estimated  a  dropout  rate  of  20%,  leading  to  a  sample  size  of  20  subjects.  To
minimise  drop-outs,  recruiting  personnel  will  emphasize  on  considering  the
requirements of the study before enrolling. In cases of dropouts, extra subjects will be
recruited  to maintain statistical power.
Statistical analysis
The primary aim is to explore the effect of MIF on mild psoriasis. Secondary outcomes
include changes from baseline to selected time-points during and post-intervention in
QoL, body weight, BMI, total body fat, inflammation and metabolic markers in serum
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and skin, and permeability markers in serum and feces.  Furthermore, differences in
dietary and physical  exercise habits will  be investigated. Comparisons will  be made
within a single arm (paired) and between both arms (unpaired). Chi-squared test and
Mann-Whitney U-test will be used to compare groups and regression-binary logistics will
be performed with identified independent variables to determine their influence on the
outcome. Demographics will be analyzed as confounding variables. Cytokine data that
are not normally distributed, and differences in cytokine levels between groups will be
analyzed using the non- parametric Mann-Whitney U test. Correlations will be assessed
using  Spearman’s  rho.  For  each  group,  we  will  use  multivariate  logistic  regression
modeling to detect associations between cytokine levels and the primary endpoint, and
to adjust  for confounding effects of age, sex, and the intervention. Cytokine data will
be log transformed prior to use in multivariate models. Pre-existing differences between
groups at baseline will be examined using a one-way analysis of variance featuring a
factor  for  diet  allocation.  Significant  differences  emerging  from these  tests  will  be
explored using appropriate post-hoc tests to adjust for multiple comparisons and isolate
the source(s) of variance. In addition to these analyses at the group level, individual
responses  will  also  be  closely  examined for  outliers  that  may  affect  interpretation.
Further analysis, such as sub-group analysis, may also be conducted in light of patterns
emerging in the final  dataset.  Baseline characteristics  of  participants  who withdraw
during  the  fasting  intervention  will  also  be  compared  against  the  final  population
using t-tests to assess tolerability. P-values will be reported to four decimal places with
p-values less than 0.0001 reported as p < 0.0001. A p value < 0.05 will be considered
statistically  significant.  Data  analysis  will  be  executed  with  SPSS  23.0  (SPSS  Inc.,
Chicago, USA) and Graphpad Prism (San Francisco, USA).
Dissemination of project findings
The findings of this study will be disseminated by various means, determined by
https://preprints.jmir.org/preprint/26405 [unpublished, peer-reviewed preprint]
JMIR Preprints Grine et al
the target audience. To reach the academic dermatology community, we will
publish  the  results  in  a  scientific  international  peer-reviewed  dermatology
journal and present our findings at (inter)national congresses with a focus on
dermatology and psoriasis. The psoriasis patient community will receive info on
the results through the National Psoriasis Foundation and the Flemish Psoriasis
League, including a laymen summary of the findings. Lastly, we will reach the
general public by communicating the main results through the research team’s
social media channels. 
RESULTS
The  study  initiation  was  delayed  due  to  the  COVID-19  pandemic.  Active
recruitment of patients began in July 2020, and the first patient was included in
October 2020. As of December 2020, we enrolled a total of 24 patients. The last
patient  last  visit  is  foreseen  in  June  2021  and  results  are  expected  to  be
published December 2021. 
DISCUSSION
Recently, psoriasis has been accepted to be a multi-morbid disease with a large
impact  from lifestyle  factors.  Obesity  has been found to  be an independent
predictor for the development of psoriasis, and to be associated with disease
severity [46]. A growing body of evidence suggests the existence of a gut-skin
axis,  which  may  be  of  importance  in  psoriasis  as  well,  urging  the  need  to
address the question of how  diet may affect the disease. To our knowledge, the
MANGO study is the first comprehensive trial to investigate the effects of MIF on
cutaneous, intestinal and mental health in a chronic skin disease. 
We expect that the MIF intervention will have beneficial effects on the psoriatic
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lesions and be associated with favorable changes in metabolic parameters. We
anticipate to detect shifts in intestinal parameters that may be associated with
skin improvement. In addition, the data generated from this trial will inform the
design for future large scale trials to evaluate the presence and role of the gut-
skin axis in psoriasis. The study additionally includes collection of cutaneous and
fecal  samples  for  future  microbiome  analysis,  if  the  intervention  proves
beneficial.
To overcome the difficulty of diet-based interventions in terms of confounding
factors and the small sample size, we have chosen the design of a prospective
cross-over randomized trial. As such, each patient will be monitored over more
than 6 months and serve as his/her own control. Another strength of this study
is the combination of clinical, biochemical and patient reported outcomes for
cutaneous, intestinal and mental parameters. Moreover, since some parameters
can  vary,  the  study  includes  two  baseline  points  in  order  to  assess  normal
variation. We opted to perform the pilot trial in a cohort of mild psoriasis who
are  not  on  systemic  agents,  to  reduce  any  confounding  effects  of
immunomodulators  that  may directly  impact  the  outcomes.  Lastly,  since  we
introduced a restrictive time window to consume the 500 kcal on fasting days,
we will be able to reduce confounding effects of the circadian rhythm [47].  A
potential limitation includes health bias amongst subjects. 
Results from this study may have multidimensional consequences and assets.
On the one hand, beneficial effects of fasting may be potentially viewed as a
non-pharmacological  add-on  treatment  for  psoriasis.  A  subset  of  psoriasis
patients  dislikes  pharmacological  treatments,  and  therefore  opt  to  gain
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additional control over their disease through a diet. On the other hand, evidence
that a free intervention may have health benefits in patients requiring costly
drugs such as biologics, may give rise to a moral dilemma: how do we define
health responsibility in terms of lifestyle with the rising healthcare costs? This
debate,  applicable  to  many  other  (chronic)  illnesses,  is  highly  relevant  and
should  not  be  postponed.  It  should  take  place  in  the  near  future,  with  a
multidisciplinary panel in a transparent manner in order to cope with results
from comparable trials.
To  conclude,  if  patients  with  psoriasis  tolerate  MIF  well  and  experience
improvement, there is potential for the diet to be widely adopted by psoriasis
sufferers in a sustainable manner. In addition, it provides a positive impact on
their general health as this diet has already proven to be effective in obesity
and seems to be effective in diabetes as well [48], two common comorbidities
associated with psoriasis. As such, we may discern the importance of the gut-
skin axis and use it to our advantage in the disease management of psoriasis.
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TABLES
Table 1: Eligibility criteria
INCLUSION CRITERIA EXCLUSION CRITERIA
 Between 18-70 years old
 Clinically diagnosed psoriasis  by a
dermatologist
 Predominantly  present  with
psoriasis vulgaris
 Present with PASI ≤ 10 at time of
enrollment
 Present  with  type  1/2  diabetes
mellitus
 Present  with  a  history  of  cardiac
condition(s)
 Present  with  comorbidities  that
cannot  be  combined  with  the
intervention (e.g. cancer)
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 Reported  stable  weight  (<  5%
weight loss/gain) for last 3 months
 Be treated exclusively with topical
treatment for psoriasis at the time
of enrollment and throughout study
 Able to give informed consent
 Willing  and  able  to  comply  with
study procedure
 Willing and able to use MyFitnessPal
app  to  record  diet  during
intervention period
 Willing  and  able  to  attend  all
scheduled visits through the study
period
 Willing and able  to  provide blood,
cutaneous  and  fecal  samples  as
stated in the procedure
 Willing  to  apply  measures  to
prevent  pregnancy  throughout
study period
 History  of,  or  current  eating
disorder (anorexia, bulimia, etc.)*
 Malnourished patients**
 Present with gout
 Be  pregnant,  having  pregnancy
plans, or breastfeeding
 Use diuretics at time of sampling
 Use of anti-, pre-, and/or probiotics
in  the  last  3  months  prior  to
enrollment  or  during  the  study
period
*Screening via the Diagnostic and Statistical Manual Method for Mental Disorders Fifth edition
(DSM-5) if indicated
**Screening via the Malnutrition Universal Screening Tool (MUST) if indicated



























https://preprints.jmir.org/preprint/26405 [unpublished, peer-reviewed preprint]
JMIR Preprints Grine et al
S TIMIN
G
















             
Psoria
sis
PASI PASI PASI PASI PASI PASI PASI PASI
BSA BSA BSA BSA BSA BSA BSA
  Phenotype     Phenotype      
Metab
olism




















  Total  body
fat







  DLQI DLQI DLQI DLQI DLQI DLQI DLQI
HADS HADS HADS HADS HADS HADS HADS
BDI BDI BDI BDI BDI BDI BDI






















PDSQ PDSQ PDSQ PDSQ PDSQ PDSQ PDSQ








E Diet MUST** MFP MFP MFP MFP MFP MFP  





















































































































*BMI based on weight measured with empty bladder**To be used in screening procedure if indicated ***Stored
until use in a follow-up project
Abbreviations: BA: Baseline analysis; BDI: Beck Depression Index; BMI: Body Mass Index; BSA: Body Surface Area;
DLQI: Dermatology Life Quality Index; DSM-5: Diagnostic and Statistical Manual of Mental Disorders Fifth edition;
FA: Final analysis; FFQ: Food Frequency Questionnaire; FU: Follow-up; HADS: Hospital Anxiety and Depression
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Scale;  IA:  Intermediate  analysis;  IPAQ:  International  Physical  Activity  Questionnaire;  MFP:  MyFitnessPal  app;
MUST:  Malnutrition  Universal  Screening  Tool;  PASI:  Psoriasis  Area  Severity  Index;  PDSQ:  Prikkelbaar  Darm
Syndroom Questionnaire (Irritable Bowel  Syndrome Questionnaire);  PSS:  Perceived Stress Scale;  TEWL: Trans
Epidermal Water Loss; VAS: Visual Analogue Scale
FIGURES
Figure  1:  Open randomized controlled  cross-over  clinical  trial  to  test  the effects of  modified
intermittent fasting on the gut-skin axis in adults with psoriasis. Cross-over includes 12 weeks
intervention  and  12  weeks  control  period.  Evaluations  include  clinical  and  biochemical
parameters. Intermediate time points are included.
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Open randomized controlled cross-over clinical trial to test the effects of modified intermittent fasting on the gut-skin axis in
adults with psoriasis. Cross-over includes 12 weeks intervention and 12 weeks control period. Evaluations include clinical and
biochemical parameters. Intermediate time points are included.
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